Company announcement - No. 8 / 2017
Passing of Zealand's Annual General Meeting in 2017
Copenhagen, April 5, 2017 - Today, Zealand Pharma A/S (Zealand) (CVR-no. 20 04 50 78) held its Annual General Meeting in 2017 at the offices of Plesner Advokatpartnerselskab, Amerika Plads 37, 2100 Copenhagen Ø, Denmark. At the meeting, all proposals presented to the General Meeting were adopted.
The General Meeting acknowledged management's report on Zealand's activities in the past financial year and Zealand's audited Annual Report for 2016 was approved. It was approved that the financial result for 2016, i.e. a loss of DKK 153,910,000, will be carried forward to the next financial year.
All board members elected by the General Meeting are elected on an annual basis. All incumbent members stood for re-election and were recommended for re-election by the Nomination Committee. All members were re-elected by the General Meeting, and hence, Zealand's Board of Directors now comprises:
- Rosemary Crane
- Catherine Moukheibir
- Alain Munoz
- Martin Nicklasson
- Michael J. Owen
- Jens Peter Stenvang (employee elected)
- Hanne Heidenheim Bak (employee elected)
- Rasmus Just (employee elected)
After the passing of the Annual General Meeting, the Board of Directors constituted itself with Martin Nicklasson continuing as Chairman and Rosemary Crane continuing as Vice Chairman.
Catherine Moukheibir, Martin Nicklasson and Rosemary Crane, with Catherine Moukheibir as Chairman, will comprise the Audit Committee.
Martin Nicklasson, Michael J. Owen and Alain Munoz, with Martin Nicklasson as Chairman, will comprise the Remuneration and Compensation Committee.
Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as the company's auditor as proposed by the Board of Directors.
The Board of Directors were authorized to allow the company to acquire, in the period until the next Annual General Meeting, its own shares for a total nominal value of up to 10% of Zealand's share capital from time to time.
Zealand's updated Remuneration Policy as well as the updated Overall Guidelines for Incentive Pay were approved as proposed by the Board of Directors.
The fees to the Board of Directors for the financial year 2017 were approved as proposed by the Board of Directors' and in accordance with the updated Remuneration Policy of the company.
The proposals by the Board of Directors to maintain the Nomination Committee as well as amending parts of the Articles of Association relating to the Nomination Committee were approved. An updated version of the rules of procedure of the Nomination Committee was also approved.
Martin Nicklasson in his role as Chairman of the Board will continue as Board representative of the Nomination Committee. Peter Benson from Sunstone Capital and Agnete Raaschou-Nielsen on behalf of LD Pension were elected to the Nomination Committee. After the passing of the Annual General Meeting the Nomination Committee elected Martin Nicklasson as Chairman of the Committee.
The proposal by the Board of Directors to disclose information pursuant to the applicable securities legislation, including announcements, in English only, and amend the Articles of Association accordingly was approved.
For further information, please contact:
Britt Meelby Jensen, President and Chief Executive Officer
Tel: +45 51 67 61 28, e-mail: bmj@zealandpharma.com
Mats Blom, Senior Vice President, Chief Financial Officer
Tel: +45 31 53 79 73, e-mail: mabl@zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of product candidates focusing on specialty gastrointestinal and metabolic diseases.
2
Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin® in the U.S. and as Lyxumia® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus®) and is marketed as Soliqua(TM) 100/33 in the U.S. and has been approved as Suliqua(TM) in Europe.
Zealand's pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase 2); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system for improved hypoglycemia control and diabetes management (Phase 2) and other earlier-stage clinical and preclinical peptide therapeutics.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.
* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN).
